Keybanc Maintains Overweight on NeuroPace, Lowers Price Target to $14

Benzinga · 1d ago
Keybanc analyst Brett Fishbin maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $18 to $14.